Quest Diagnostics has agreed to acquire select assets of Spectra Laboratories, the renal-specific laboratory testing division of Fresenius Medical Care, as part of a definitive acquisition agreement, the companies announced Monday.
Under a separate agreement, Quest, located in Secaucus, will provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care’s owned and affiliated clinics across the United States.
The acquisition will add dialysis-related water testing to Quest’s portfolio, allowing Fresenius to streamline operations while leveraging Quest’s clinical expertise and national laboratory network. The move aims to improve testing efficiency and turnaround times, as Quest’s widespread lab network will reduce transportation times and provide faster results for some services.
“This agreement allows us to focus on our core business of delivering world-class dialysis care while integrating Quest’s expertise in laboratory medicine to enhance patient and provider experiences,” said Helen Giza, CEO of Fresenius Medical Care.
Jim Davis, chairman, CEO, and president of Quest Diagnostics, said the partnership will expand Quest’s role in chronic kidney disease testing, a major health concern affecting approximately 35.5 million Americans. “By leveraging our national scale, we can bring high-quality testing closer to Fresenius clinics and the patients they serve,” Davis said.
Financial details were not disclosed. The acquisition is expected to close in the second half of 2025, pending regulatory approvals, with a full transition of services anticipated by early 2026.
Fresenius Medical Care, which operates more than 3,700 dialysis clinics worldwide, is in the final phase of a three-year turnaround strategy aimed at divesting non-core assets and optimizing its portfolio for sustainable growth.
Chronic kidney disease is one of the most prevalent and costly chronic illnesses in the U.S., often progressing to end-stage kidney disease (ESKD), which requires dialysis or transplantation. More than 800,000 people in the U.S. undergo dialysis, which requires regular laboratory and water quality testing to ensure patient safety.
